The serum concentrations of the Th2 cytokines (IL-4 and IL-10) in tumor-bearing patients were significantly higher than those with resected NSCLC before immunotherapy.The post-therapy Th1 cytokine (INF-γ) level in patients with resected NSCLC significantly increased from the pre-therapy level. In tumor-bearing patients, significantly enhanced post-therapy Th2 cytokine (IL-4 and IL-10) levels were found. This evidence concerns the gene IL10 and non-small cell lung carcinoma.